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Abstract
Purpose—The purpose of this cross-sectional study is to explore primary care providers’ (PCPs)
perceptions about barriers to initiating insulin among patients. Studies suggest that many patients
with poorly controlled type 2 diabetes do not receive insulin initiation by PCPs.
Methods—As part of the TRIAD study, we conducted structured interviews in health systems in
Indiana, New Jersey, and California, asking PCPs about the importance of insulin initiation and
factors affecting this decision. We calculated proportions choosing each multiple-choice response
option and listed the most frequently offered open-ended response categories.
Results—Among 83 PCPs, 45% were women, 60% were Caucasian, and they averaged 13.4
years in practice. Four-fifths of PCPs endorsed guideline-concordant glycemic targets, but 54%
individualized targets based on patient age, life expectancy, medical co-morbidities, self-
management capacity, and willingness. Most (64%) reported that many patients were resistant to
new oral or insulin therapies due to fears about the therapy and what it meant about their disease
progression. Two-thirds (64%) cited patient resistance as a barrier to insulin initiation, and 43%
cited problems with patient self-management, including cognitive or mental health issues,
dexterity, or ability to adhere.† Eighty percent felt that patient non-adherence would dissuade
them from initiating insulin at least some of the time.
Conclusions—PCPs perceived that patient resistance and poor self-management skills were
significant barriers to initiating insulin. Future studies should investigate whether systems-level
interventions to improve patient-provider communication about insulin and enhance providers’
perceptions of patient self-management capacity can increase guideline-concordant, patient-
centered insulin initiation.
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Although guidelines recommend the early initiation of insulin therapy among type 2
diabetes who do not achieve adequate glycemic control on oral agents,1,2 many primary care
providers do not initiate insulin therapy even when their patients are not adequately
controlled. In a retrospective study of 7208 patients, from time of diagnosis to the start of
insulin therapy, the average patient spent nearly 5 years with their hemoglobin A1c >8% and
10 years with their hemoglobin A1c >7%.1,2
The decision to initiate insulin may be affected by patient-, provider-, and systems-level
factors. For example, research suggests that patients resist initiating insulin – either by
failing to fill a new prescription for insulin or to refill an existing prescription – because of
fears about discomfort or harm from the therapy, limited understanding of its risks and
benefits, or uncertainty about self-management.3,4 Patients’ perceptions about medication
intensification or initiation may differ markedly from provider recommendations; patients
may view the event as evidence of personal failure and a potentially health risk itself (rather
than reducing future complication risk) and may consider de-escalation a primary goal.5
Other studies have examined potential provider reasons for clinical inertia – or failure to
intensify medication therapies – including providers’ overestimating the quality of care they
provide, use of “soft” rationalizations to avoid intensification, and lack of organizational
mechanisms to help providers track and achieve therapeutic goals.6 Provider frustrations
with their own inability to address patient or health system barriers may also play a role in
deciding not to intensify therapy.7 At the systems level, care facilities may lack the support
mechanisms needed to assist providers in initiating more complex therapies such as insulin.
However, deferring insulin initiation based on the benefits and risks for individual patients
may be appropriate patient-centered care. Recent studies have raised uncertainty about the
cardiovascular benefit of tight glycemic control among type 2 diabetics and concerns about
the risks and long-term consequences of hypoglycemia.8–10 The American Geriatric Society
and the American Diabetes Association clinical guidelines recommend an individualized
approach to glucose-lowering for older patients, emphasizing the need to adjust glycemic
targets based on life expectancy, geriatric syndromes, and quality of life.1,11 As a result of
these and other factors, providers may be left with clinical dilemmas when they need to
decide whether to initiate insulin for individual type 2 patients.
We conducted this study to investigate primary care providers’ beliefs regarding the
importance of initiating insulin to achieve glycemic control targets and factors affecting
their decision to initiate insulin therapy among patients with poorly controlled diabetes.
Methods
Study Design and Sample Population
We conducted structured interviews with primary care providers in three states. Providers
were drawn from the Indiana University Medical Group (IUMG), community-based primary
care physicians in New Jersey, and the Kaiser Permanente Medical Group of Northern
California (KPMG). This cross-sectional study was part of the Insulin Starts Project, which
was in turn an ancillary study of a larger ongoing CDC and NIDDK-funded study of the
quality of care and self-care for people with diabetes in U.S. managed care settings, The
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Translating Research Into Action for Diabetes (TRIAD). The TRIAD study design and
methods have been previously reported.12
Eligible participants were primary care providers (PCPs) – physicians or nurse practitioners
– with at least two half-day clinic sessions per week and panels with at least 50 patients with
type 2 diabetes, including patients who had a hemoglobin ≥8% on maximal doses of 2 oral
hypoglycemic agents in the past 18 months (i.e., patients eligible for a separate study within
TRIAD.3 Physicians-in-training were excluded. Eligible providers were identified by the
health plans.
Data Collection
Providers were recruited by TRIAD staff at each of three TRIAD translational research
centers participating in this study. We mailed letters to providers who cared for patients
deemed eligible for the patient survey asking for approval to recruit their patients and
inviting them to participate in this provider study. Recruiters aimed to enroll 90 PCPs from
the three health plans, and provider recruitment was concluded after reaching enrollment
targets. Providers received $100 for their participation.
Research assistants conducted one-hour structured telephone interviews at a time and date
convenient for providers. The instrument contained open-ended questions and follow-up
probes about the following topics: glycemic goals, factors contributing to insulin initiation,
barriers to insulin initiation, choice of insulin once initiated, and barriers to insulin
adherence. Questions were not linked to specific patients, but rather asked providers to
consider an average patient in their panel with diabetes. Providers also reported their
demographic characteristics. This analysis focuses on interview items assessing factors that
affect PCPs’ choice of glycemic targets, contribute to their decisions to initiate insulin
therapy, and serve as barriers to their decisions to initiate insulin therapy. The Institutional
Review Boards of all three TRIAD translational research centers approved this study.
Data Analysis
We calculated the proportions of participants choosing each response option. For open-
ended response options, we listed the most frequently offered responses, as categorized by
the authors. Respondents were allowed to respond to multiple items relevant to an individual
question.
Results
Eighty-three PCPs completed interviews. Their average age was 45.6 (SD 8.9) and average
time in practice 13.4 years (SD 9.5). Half (45%) were women; 60% were white, 11%
African-American, 10% of Asian descent. Twenty-seven percent were from California, 37%
from Indiana, and 37% from New Jersey.
Glycemic Goals
Most PCPs endorsed a guideline-concordant glycemic target, with 69% choosing
hemoglobin A1c under 7.0 as an ideal target for good control; 13% chose values between
6.0 and 6.9 and 18% chose values between 7.2 and 8.0. However, over half (54%) perceived
a need to raise the target A1c value depending on patient factors. Providers most frequently
chose the following patient factors as reasons to accept higher glycemic targets: advanced
age or shortened life expectancy (54%), presence of co-morbidities (34%), poor self-
management capacity due to poor cognitive abilities (35%), low educational level or poor
health literacy (34%), and patients’ unwillingness to self-manage their diabetes (33%).
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Factors Contributing to Insulin Initiation
When offered a list of potential factors that would lead to initiating insulin, 83% of PCPs
chose failure to reach anti-hyperglycemic goals using other therapies, while some providers
cited medication contraindications (27%) or side effects (23%) to oral agents. Only 7% felt
that patients’ requests for insulin were a factor.
Barriers to Initiating Insulin
When asked for the reasons that they decided not to initiate insulin therapy, 64% cited
patient refusal or resistance and 43% cited concerns about patients’ lack of self-management
skills. PCPs indicated that it was somewhat or very common that patients will not try new
therapies proposed by providers or adhere to these therapies once started. Two-thirds of
PCPs (67%) felt that at least 10% of their patients would refuse insulin and that at least 10%
who start insulin would decide not to continue. The primary reasons that PCPs thought
patients refuse to initiate insulin included: fear of injections (97%), patients’ beliefs that
using insulin means they will get sicker (38%), and the inconvenience associated with
injections and self-monitoring of glucose (22%). Similarly, PCPs reported that the most
common reasons patients fail to adhere to insulin therapy were inconvenience (34%), fear of
hypoglycemia (30%), injection discomfort (28%), and inability to self-manage with insulin
(15%). Forty-one percent of PCPs felt that language barriers would be a challenge when
starting a patient on insulin in their practice environment.
When asked for reasons that would lead them to deem a patient incapable of managing
insulin therapy, 49% selected self-management skills, 35% blindness, 33% poor cognitive
abilities, and 27% psychological issues. Finally, four-fifths of PCPs felt that, for patients
with low levels of adherence to oral agents, they would not initiate insulin some of the time
(43%), most of the time (34%), or ever (5%).
Discussion
In this multi-site study, PCPs endorsed the importance of achieving glycemic goals and of
initiating insulin to reach glycemic targets for those uncontrolled on oral agents. However,
most believed that several factors would mitigate their ability to intensify therapy in general
and to initiate insulin in particular. Most of the respondents identified patient factors as a
prime contributor to decisions to not initiate insulin. The respondents reported that at least
10% of their patients would refuse starting or continuing insulin therapy due to fear of the
injections, fear of insulin, or the inconvenience of self-management. For most providers, this
perceived resistance or lack of self-management skills in their patients was a barrier to
initiating insulin therapy, and prior non-adherence to oral agents would dissuade most PCPs
from initiating insulin with some patients.
Provider decision-making about whether to initiate or intensify medication therapy is a
complex process affected by multiple factors,6 and clinical inertia is considered a major
reason for inadequate metabolic control in diabetics.13–15 In prior studies, rates of
appropriate medication intensification for poorly controlled hemoglobin A1c have ranged
from 46 to 66%.14,16,17 However, these studies did not investigate the relative contribution
of PCPs’ attitudes to their clinical inertia.
Our results lend insights into how providers incorporate their beliefs about patients’ prior
adherence, preferences, and treatment risk and burden into their decision-making. Indeed,
while most providers aimed for a hemoglobin A1c target of <7.0%, most also would adjust
this target or refrain from starting insulin, a modification that is consistent with established
guidelines.1,8,11 Given recent studies highlighting the linkage between inadequate health
literacy among insulin users and hypoglycemia risk, and the long-term and acute
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consequences of hypoglycemia events,9,10,18 providers’ concerns about initiating insulin
therapy may be both patient-centered and medically appropriate. With the potential for
physical, psychological, and financial burdens of intensive therapy and monitoring, some
have questioned the wisdom of applying quality indicators to promote tight glycemic control
among all type 2 diabetics, arguing for more conservative prescribing practices.19,20
However, it is unclear how accurate PCPs are in their assessment of patients’ preferences,
concerns, and self-management capacity. A separate part of the TRIAD Insulin Starts
Project assessed attitudes towards insulin among patients with poorly controlled diabetes
who fail to fill their first insulin prescriptions and found similar barriers to insulin therapy
reported from the patient perspective.3 Fear of injections occurred for 30% of patients who
failed to start insulin, and 97% of PCPs recognized that this is a major reason for patients’
failure to initiate insulin therapy. Meanwhile, 55% of patients who did not fill their insulin
prescription felt that medication risks and benefits were not adequately explained by their
providers, with 51% reported difficulty learning about their condition because of problems
understanding written information (i.e., inadequate health literacy). Among patients who did
not fill their insulin prescriptions, significant proportions expressed moderate to extreme
concerns about their ability to give themselves shots (42%) and potential negative impact on
their jobs (33%) and their social lives (38%).3 This suggests that some of these potential
barriers might be addressed by more patient education and counseling and more focus on the
quality of providers’ communication regarding insulin initiation.
Providers’ assumptions about self-management capacity could also contribute to disparities
in intensification in response to suboptimal glycemic control. In our study, PCPs considered
limited health literacy and language issues to be barriers to self-management, which is itself
a barrier to insulin initiation. A recent study did find that patients with limited health literacy
were 30–40% more likely to experience hypoglycemia compared to those with adequate
health literacy.9 However, a patient’s capacity for self-management is not a static factor, and
health care systems interventions can enhance diabetes self-management among diverse
patient populations.21,22 For example, a randomized controlled trial of automated telephone
self-management support among a low income population with limited English proficiency
and poorly controlled diabetes demonstrated significant improvements in self-management
behavior, including increased participation in self-management behaviors and physical
activity.22
Providers’ beliefs that some patients lack the willingness or capacity to take insulin may
reflect a need for more resources to help providers engage patients in effective shared
decision-making and enhance patients’ capacity for self-management. In one study of older
patients with diabetes, the higher patient ratings of their providers’ provision of information
and participatory decision-making style were significantly associated with self-management
behaviors such as diet, exercise, glucose monitoring, and foot care, and patients’ ratings of
their self-management were associated with glycemic control.23
Our study highlights the prominence of perceived patient non-adherence in dissuading
providers from initiating insulin. Consistent with our findings, another study suggested that
academic general internal medicine physicians emphasized patient adherence, along with
patient fear of injections and patient desire to prolong non-insulin therapy as major insulin
barriers.24 In one study examining pharmacy claims, 23% of poorly controlled
hyperglycemic patients had evidence of poor adherence and lack of treatment intensification
by providers.17 Still, 30% of poorly controlled, hyperglycemic patients had no treatment
intensification despite a lack of evidence of poor medication adherence, suggesting that
providers may not accurately assess non-adherence in their patients or that this does not
explain clinical inertia entirely.17 Meanwhile, interventions focused on improving
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medication adherence have been complex and marginal in effectiveness.25 More strategies
are needed to help providers assess and manage non-adherence and to determine whether
maintaining, decreasing, or intensifying a regimen is the most effective or patient-centered
recommendation.
This study is limited in that, although the providers were drawn from three different health
systems caring for diverse patient populations, our findings may not be generalizable to
providers in other systems caring for different populations. We did not assess formally
validity or reliability of the interview instrument. Because we asked PCPs to reflect on
patients in general, our results may be susceptible to recall bias by providers attempting to
recall factors in past decision-making experiences with their patient panel. An interview
conducted immediately following a specific decision regarding a specific patient –
particularly if paired with an interview with the patient itself – might be less subject to recall
bias, but might also yield different insights into the insulin initiation decision-making
process. Finally, our limited sample size precludes us from determining whether PCP factors
such as years in practice or clinic site are related to attitudes. the study methodology asked
PCPs to reflect on their patients in general;
Conclusions
In summary, although they believed in the importance of tight glycemic targets, these PCPs
perceived that patient resistance and poor self-management skills were significant barriers to
initiating insulin therapy. Consequently, many patients remain on less intensive therapies.
Some of the factors identified may be amenable to education and counseling. However,
PCPs may defer insulin therapy based on reasonable concerns about patients’ capacity to use
safely an intensive therapy that requires extensive self-management. Future studies should
investigate whether systems-level interventions to improve patient-provider communication
about insulin therapy and enhance patient self-management can decrease providers’
perception of these barriers and increase the likelihood of guideline-concordant, patient-
centered insulin initiation.
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Implications / Relevance for Diabetes Educators
• In this study in three health systems, half of primary care providers believed in
the need to individualize targets based on patient age, life expectancy, medical
co-morbidities, self-management capacity, and willingness.
• Most primary care providers cited patient resistance, poor self-management
skills, and non-adherence as barriers to insulin initiation
• To increase guideline-concordant, patient-centered insulin initiation, managed
care leaders should consider strategies to improve patient-provider
communication about insulin and enhance providers’ perceptions of patient self-
management capacity.
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Table 1
Primary care providers’ attitudes about intensifying anti-hyperglycemic therapy and initiating insulin among
poorly controlled diabetics, from a telephone study in three health care systems (n=83)
Attitudes %
Highest hemoglobin A1c for which patient would be in good control
      6.0 – 6.9 13
      7.0 69
      >7.0 – 8.0 18
Reasons to adjust glycemic targets*
      Age / life expectancy 54
      Ability to self-manage due to cognitive abilities 35
      Medical co-morbidities 34
      Ability to self-manage due to education level / health literacy 34
      Patient willingness to self-manage 33
Reasons to initiate insulin*
      Failure to reach glycemic goals using other therapies 83
      Contraindications to oral agents 27
      Side effects with oral agents 23
Proportion of patients failing to try oral medications†
      <10% 41
      10% 33
      15–30% 24
      33–50% 2
Proportion of patients trying but failing to continue oral medications†
      <10% 23
      10% 41
      15–30% 28
      33–50% 8
Proportion of patients failing to try insulin†
      <10% 34
      10% 23
      15–30% 33
      35–70% 9
Proportion of patients trying but failing to continue insulin†
      <10% 39
      10% 28
      15–30% 26
      33–55% 7
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Attitudes %
Perceived reasons why patients refuse to initiate insulin*
      Fear of injections 97
      Beliefs that insulin will mean they will get worse, go blind, die sooner, etc. 38
      Inconvenience due to injections and self-monitoring blood glucose 22
Perceived reasons why patients refuse to continue or adhere poorly to insulin*
      Inconvenience due to injections and self-monitoring blood glucose 34
      Fear of hypoglycemia 30
      Discomfort from injections 28
      Inability to self-manage with insulin. 15
Reasons for deciding NOT to initiate insulin therapy*
      Patient refusal or resistance 64
      Concerns about patient’s self-management skills 43
      Discomfort from injections 28
Prior non-adherence would lead PCP to decide with this type of patient to
      Never initiate insulin 5
      Not initiate insulin most of the time 34
      Not initiate insulin some of the time 43
      Rarely not initiate insulin 17
*
Respondents were asked to select >1 response, so proportions do not add up to 100%
†Open-ended responses were solicited, then categorized into intervals during analysis based on the actual responses in those categories.
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